glycopeptide

Phleomycin is one of the anticancer glycopeptide antibiotics which cause DNA cleavage. It is similar to Bleomycin which binds and intercalates DNA to damage the integrity of the double helix.

Bleomycin sulfate is a glycopeptide antibiotic with antitumor activity. It is commonly used as a DNA-damaging agent and DNA synthesis inhibitor. It functions by inducing DNA strand breaks without affecting RNA strands. Bleomycin sulfate is widely used in cancer research and for establishing pulmonary fibrosis animal models.

Vancomycin is a glycopeptide antibiotic that exerts its antibacterial activity by inhibiting the second stage of cell wall synthesis in susceptible bacteria. It also alters cell membrane permeability and selectively inhibits RNA synthesis. Vancomycin is commonly used to treat severe infections resistant to other antibiotics and is frequently employed in experimental studies to induce kidney injury models.

Vancomycin hydrochloride (Vancomycin HCl) is a glycopeptide antibiotic that targets Peptidoglycan in bacterial cell wall synthesis. Vancomycin hydrochloride is mainly used for the treatment of severe Gram-positive bacterial infections.

Teicoplanin (MDL-507) is a semisynthetic glycopeptide antibiotic, used to treat Gram-positive bacteria.

Bleomycin A5 (Pingyangmycin), a glycopeptide antibiotic that is orally active, functions as an antineoplastic agent, an apoptosis inducer, and a bacterial metabolite [1] [2].

Vancomycin hydrochloride (Standard) is the standard substance of Vancomycin hydrochloride, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Vancomycin hydrochloride (Vancomycin HCl) is a glycopeptide antibiotic that targets Peptidoglycan in bacterial cell wall synthesis. Vancomycin hydrochloride is mainly used for the treatment of severe Gram-positive bacterial infections.

Liposidomycin C exhibits antibacterial properties, though its activity is relatively weak. It shows significant inhibitory effects on mycobacteria with a minimum inhibitory concentration (MIC) of 0.16 μg/mL. Additionally, Liposidomycin C inhibits glycopeptide biosynthesis, effectively suppressing Escherichia coli glycopeptide biosynthesis with an IC50 of 0.03 μg/mL.

Liposidomycin B exhibits antibacterial properties, although its activity is relatively weak. It shows a significant inhibitory effect on mycobacteria with an MIC of 0.16 μg/mL. Additionally, Liposidomycin B hinders glycopeptide biosynthesis, effectively inhibiting glycopeptide biosynthesis in Escherichia coli with an IC50 of 0.03 μg/mL.

Parvodicin B1 is a glycopeptide antibiotic effective against Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Enterococcus faecalis. It functions by inhibiting the synthesis of bacterial cell walls.

Parvodicin B2 is a glycopeptide antibiotic that inhibits Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Enterococcus faecium. It functions by preventing the synthesis of bacterial cell walls.

Helvecardin B is a glycopeptide antibiotic with potent activity against both aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Liposidomycin A exhibits antibacterial properties, though its activity is relatively weak. It demonstrates significant inhibitory effects on mycobacteria, with a minimum inhibitory concentration (MIC) of 0.16 μg/mL. Additionally, Liposidomycin A inhibits glycopeptide biosynthesis, effectively suppressing Escherichia coli glycopeptide biosynthesis with an IC50 of 0.03 μg/mL.

Parvodicin A is a glycopeptide antibiotic that exhibits inhibitory effects against Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Enterococcus faecalis.

Parvodicin C4 is a glycopeptide antibiotic that exhibits inhibitory effects against Staphylococcus aureus, Staphylococcus epidermidis, hemolytic Staphylococcus, and Enterococcus faecalis.

Parvodicin C3 is a glycopeptide antibiotic that exhibits inhibitory effects on Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Enterococcus faecium.

Parvodicin C2, a glycopeptide antibiotic derived from A. parvosata and part of the parvodicin complex, serves as a component of the A40926 antibiotic complex utilized as a precursor for synthesizing dalbavancin. It exhibits activity against methicillin-sensitive and methicillin-resistant strains of S. aureus, S. epidermidis, S. saprophyticus, S. hemolyticus, and E. faecalis.

N-Demethylvancomycin is a glycopeptide antibiotic that can be extracted from Nocardia orientalis and exhibits activity against various strains of Staphylococcus aureus and Staphylococcus epidermidis. It is utilized in research related to infections.

Actinoidin A is a glycopeptide antibiotic (antibiotic) effective against Gram-positive bacteria.

Helvecardin A is a glycopeptide antibiotic with potent activity against both aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.